Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoven versus Vaminolact in preterm very low birth weight infants requiring parenteral nutrition
NL-OMON34823Phase 3Active, not recruiting
- Sponsor
- Fresenius Kabi
- Start
- Jun 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in deficiency disorders comparing Neoven with Vaminolact (2 arms). Primary endpoints: Hyperammonemia, Metabolic acidosis and 3 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
NeovenVaminolact
03
Conditions
deficiency disorders
Beyond the preview
Go deeper on NL-OMON34823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34823.